From TRIUMF, BC Cancer Agency, UBC, Centre for Probe Development and Commercialization, Lawson Health Research Institute, and Advanced Applied Physics Solutions, Inc., the CycloMed99 team brings together:
- Nuclear chemists;
- Technicians; and
The CycloMed99 team is headed by Paul Schaffer. The key TRIUMF members are:
Dr. Paul Schaffer
Principal Investigator; Technical Lead: Tc-99m Purification/Isolation
Dr. Schaffer is Head of the Nuclear-Medicine Division at TRIUMF.
He comes to TRIUMF from GE’s Global Research Centre where he was responsible for the research and development of novel radiotracers for GE Healthcare’s radiopharmaceutical pipeline. His expertise is in radiochemistry and he has over a decade of experience working on technetium-based radiopharmaceuticals. He recently obtained funding from WD Canada to bolster TRIUMF’s GMP compliance through the construction of a clean facility for tracer production.
Dr. Thomas J. Ruth
TRIUMF and the BC Cancer Agency
Special Advisor, Emeritus
Dr. Ruth is a nuclear chemist by training with more than four decades of experience.
He is an expert in isotope production, extraction, and purification; radiochemical synthesis and formulation; and molecular imaging using PET-based compounds.
He oversaw operation of the TRIUMF medical-isotope cyclotron for routine production of clinical research isotopes for the Pacific Parkinson’s Research Centre and the BC Cancer Agency. He has also pioneered the design and implementation of target technologies.
Ruth is an internationally recognized expert in nuclear medicine and regularly serves on IAEA and U.S. National Academies committees.
Mr. Ken Buckley
Project Manager; Technical Support: Targetry
Mr. Buckley has over 20 years of experience in target research and design.
Mr. Buckley maintains a deep understanding of the business of making medical isotopes and has played a major role in the implementation of TRIUMF’s Quality Mananagement System and has also served as project manager for a number of team-based projects at TRIUMF.
Dr. Stefan Zeisler
Co-investigator; Project Manager; Technical Support: Targetry, Radiochemistry, Isotope Recycling
Dr. Zeisler is former Manager of TRIUMF’s Applied Technology Group (ATG), which is responsible for the operation of the TRIUMF Isotope Production Facilities. He is trained as a radiochemist and has specialized expertise in accelerator targetry, isotope purification and radiopharmaceutical chemistry. Dr. Zeisler maintains a deep understanding of the business aspects of medical radioisotope production and the commercialization of related technologies.
Ms. Hanemaayer has a background in organic chemistry and has many years of experience in solid targets, particularly with refractory-metals and liquid-metal targets. She also has experience in writing and managing Q/A documentation, laboratory management, and GMP.
|Mr. McDiarmid is an Electromechanical Engineer. He has five years experience with TRIUMF’s Applied Technologies Group helping to run three 30 MeV cyclotrons for medical isotope production. He has his B.Apsc in Engineering Physics from UBC.|
|Mr. Dodd is an Electromechanical Engineer with decades of experience in designing automated systems for the remote manipulation of large quantities of radioactivity. Mr. Dodd's experience will allow the TRIUMF team to build and distribute automated purification units to our partners in order to separate Tc-99m from the Mo-100 target material. Prior to his time at TRIUMF, Mr. Dodd spent 10 years managing the PET cyclotron in Aberdeen, Scotland. |
About the BC Cancer Agency
The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. The BC Cancer Foundation raises funds to support research and enhancements to patient care at the BC Cancer Agency. To learn more, visit http://www.bccancer.bc.ca/.
About the Centre for Probe Development and Commercialization (CPDC)
CPDC discovers, develops and distributes molecular imaging probes for the early diagnosis of diseases and to assess the effectiveness of treatments. An important part of Ontario's health system, CPDC provides a reliable, daily supply of imaging probes to hospitals across the province. CPDC also works collaboratively with industry and academic partners, offering the research, manufacturing and regulatory expertise needed to move innovative probe technology and new therapeutic drugs from R&D labs to clinical use. CPDC, located on the McMaster University Campus, is a Centre of Excellence for Commercialization and Research, part of the Networks of Centres of Excellence Program. It is supported by the Ontario Institute for Cancer Research, GE Healthcare, Cancer Care Ontario, and McMaster University. To learn more, visit http://www.imagingprobes.ca and http://www.imagingprobes.ca/research/NISP.
Lawson Health Research Institute, located in London, Ontario, is one of Canada's largest and most respected hospital-based research institutes. As the research arm of London Health Sciences Centre and St. Joseph's Health Care, London, and working in partnership with The University of Western Ontario, Lawson is committed to furthering scientific knowledge to advance health care around the world. Its state-of-the-art, 6,000 sq. ft. Nordal Cyclotron & PET Radiochemistry Facility opened on March 31, 2010 and includes a GE PETtrace 8 cyclotron with proton and deuteron acceleration capability, class 100 shielded hot cells, and automated chemistry units for producing F-18 and C-11 radiopharmaceuticals – all to GMP specifications. To learn more, visit http://www.lawsonimaging.ca and http://impatiens.sjhc.london.on.ca/drupal/node/1649.
TRIUMF is Canada's national laboratory for particle and nuclear physics. Located on the south campus of the University of British Columbia, TRIUMF is owned and operated as a joint venture by a consortium of the following Canadian universities, via a contribution through the National Research Council Canada: University of Alberta, University of British Columbia, University of Calgary, Carleton University, University of Guelph, University of Manitoba, McMaster University, University of Northern British Columbia, Université de Montréal, Queen's University, University of Regina, Saint Mary's University, Simon Fraser University, University of Toronto, University of Victoria, University of Winnipeg, and York University. To learn more, visit http://www.triumf.ca and http://www.triumf.ca/cyclomed99.